TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent z rozpoznanym zaawansowanym lub przerzutowym rakiem jelita grubego.
- •Pacjent ma 18 lat lub więcej i zgadza się na udział w badaniu.
- •W badaniu stwierdzono obecność guza, który można zmierzyć.
- •Ogólny stan zdrowia pacjenta pozwala na aktywność (stopień 0-1 według skali ECOG) i przewidywana długość życia wynosi co najmniej 12 tygodni.
✗ Disqualifies
- •Wcześniejsza silna reakcja alergiczna lub nadwrażliwość na składniki badania.
- •Przyjmowanie innego eksperymentalnego leku w ciągu ostatnich 28 dni lub podczas trwania badania.
- •Przyjmowanie wysokich dawek sterydów lub innych leków osłabiających układ odpornościowy.
- •Historia poważnych chorób autoimmunologicznych (organizm atakuje sam siebie).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (41)
Arizona Oncology Associates
Tucson, United States
University of Southern California
Los Angeles, United States
Hoag Memorial Hospital
Newport Beach, United States
Rocky Mountain Cancer Centers
Denver, United States
Yale Cancer Center
New Haven, United States
Christiana Care Helen F. Graham Cancer Center
Newark, United States
John Hopkins Kimmer Cancer Center
Washington D.C., United States
Florida Cancer Specialists
Daytona Beach, United States
Florida Cancer Specialists
Fleming Island, United States
Ocala Oncology Center
Ocala, United States
AdventHealth Research Institute
Orlando, United States
Illinois Cancer Specialists
Arlington Heights, United States
University of Illinois
Chicago, United States
Indiana University
Indianapolis, United States
Norton Cancer Institute
Louisville, United States
American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders
Bethesda, United States
Maryland Oncology Hematology
Silver Spring, United States
Dana-Farber Cancer Institute
Boston, United States
START Midwest
Grand Rapids, United States
Regions Hospital Cancer Care Center
Saint Paul, United States
Washington University in St Louis
St Louis, United States
Nebraska Cancer Center Oncology Hematology West P.C.
Omaha, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Stony Brook University
Stony Brook, United States
University of Cincinnati
Cincinnati, United States
Zangmeister Cancer Center
Columbus, United States
The University of Toledo
Toledo, United States
University of Oklahoma
Oklahoma City, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
Medical University of South Carolina
Charleston, United States
Sarah Cannon Research Institute
Nashville, United States
Vanderbilt - Ingram Cancer Center
Nashville, United States
Texas Oncology - Dallas
Dallas, United States
START Dallas
Fort Worth, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Texas Oncology - Paris
Paris, United States
NEXT Oncology
San Antonio, United States
NEXT Oncology Virginia
Fairfax, United States
Northwest Medical Specialties
Tacoma, United States
Northwest Cancer Specialists
Vancouver, United States
Trial contact
Tizona Therapeutics, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.